LLY
Eli Lilly and Company
LLY has the edge over TELA overall, supported by stronger fundamentals and lower modeled downside.
TELA
TELA Bio, Inc.
TELA's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TELA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
TELA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TELA PE Valuation
TELA has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over TELA on the outlook, with more favorable revenue expectations.
TELA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TELA's losses to shrink, with revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TELA on earnings quality, reporting a profit while its opponent remains loss making.
TELA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.74 | +$0.09 |
| Q2 2026 | -$0.77 | +$0.29 |
| Q1 2026 | -$0.79 | +$0.56 |
| Q4 2025 | -$0.83 | +$0.50 |
| Q3 2025 | -$0.83 | +$0.83 |
| Q2 2025 | -$1.06 | +$0.63 |
| Q1 2025 | -$1.35 | +$0.29 |
| Q4 2024 | -$1.33 | +$0.71 |
TELA is still losing money, but far less than before: $0.74 per share over the past year, against $2.87 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TELA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TELA on profitability, with a higher operating margin.
TELA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | -8.4% |
| Q2 2026 | $19.3M | -4.5% |
| Q1 2026 | $19.1M | +2.9% |
| Q4 2025 | $20.9M | +18% |
| Q3 2025 | $20.7M | +9.1% |
| Q2 2025 | $20.2M | +26% |
| Q1 2025 | $18.5M | +12% |
| Q4 2024 | $17.6M | +3.8% |
TELA's revenue has held roughly level: $19M last quarter, down 8.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -38% | -1.9 points |
| Q2 2026 | -48% | -3.2 points |
| Q1 2026 | -55% | +1.3 points |
| Q4 2025 | -32% | +16 points |
| Q3 2025 | -37% | +13 points |
| Q2 2025 | -45% | +27 points |
| Q1 2025 | -57% | -28 points |
| Q4 2024 | -47% | +25 points |
TELA's operating margin was −38% last quarter, down 1.9 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TELA on cash generation, producing positive trailing cash flow while its opponent burns cash.
TELA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.7M | -$2.8M |
| Q2 2026 | -$9.4M | -$1.4M |
| Q1 2026 | -$11.3M | -$1.5M |
| Q4 2025 | -$5M | +$2.8M |
| Q3 2025 | -$5.9M | +$3.2M |
| Q2 2025 | -$8M | +$3M |
| Q1 2025 | -$9.8M | +$4.9M |
| Q4 2024 | -$7.8M | +$3.5M |
TELA has burned cash in almost every quarter: −$34M over the past year, against −$32M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TELA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TELA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +275K shares |
| 1 year | +27% | +12.3M shares |
| 3 years | +148% | +34.4M shares |
| 5 years | +299% | +43.2M shares |
| Available history | +406% | +46.3M shares |
TELA has 58M diluted shares, up 27% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TELA Net Leverage
TELA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TELA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.7 | Neutral |
| Stochastic | 25.3 | Neutral |
TELA's weekly RSI is 48 (neutral) and its Stochastic is 25 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TELA PE vs Healthcare Sector
TELA has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TELA on trend strength, trading above more of its moving averages.
TELA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 13% below |
| 20 week MA | $0.88 | 2.3% below |
| 50 week MA | $0.88 | 2.3% below |
| 100 week MA | $1.34 | 36% below |
| 200 week MA | $4.07 | 79% below |
TELA is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TELA on returns for 2026, with the stronger performance.
TELA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.7 | $16.0 | +26% |
| 2021 | $16.0 | $12.5 | -22% |
| 2022 | $12.5 | $11.3 | -10% |
| 2023 | $11.3 | $6.62 | -41% |
| 2024 | $6.62 | $2.91 | -56% |
| 2025 | $2.91 | $1.14 | -61% |
| 2026 YTD | $1.14 | $0.86 | -25% |
TELA has finished five years in a row lower, and it's down 25% so far in 2026.